Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan
Chien‐Yu Cheng, Yulin Lee, Cheng‐Pin Chen, Yi‐Chun Lin, Chun-Eng Liu, C Liao, Shu‐Hsing Cheng
Abstract
An increase of Ct values was 0.9 per day in 2 cases of COVID-19 treated with lopinavir/ritonavir (LPV/r), an increase was 1.0 per day in 3 cases without LPV/r through illness day 1-10, indicating that LPV/r did not shorten the duration of SARS CoV-2 shedding.
Topics & Concepts
LopinavirLopinavir/ritonavirRitonavirMedicineCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakPneumoniaVirologyInternal medicineViral loadHuman immunodeficiency virus (HIV)Antiretroviral therapyInfectious disease (medical specialty)OutbreakDiseaseCOVID-19 Clinical Research StudiesInfectious Encephalopathies and EncephalitisSARS-CoV-2 and COVID-19 Research